Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 1 000 UNITS AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 1 000 UNITS AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (Xa), thereby preventing thrombus formation and extension.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
IV infusion: Initial bolus 80 units/kg, then 18 units/kg/h continuous IV infusion; titrate to aPTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life 1–2 hours (dose-dependent; increases with higher doses due to saturable clearance). Clinical context: shorter half-life after IV bolus, prolonged in hepatic/renal impairment.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal (primarily via reticuloendothelial system, desulfation, and degradation; small amount unchanged in urine <10%). Biliary/fecal excretion minor.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte